Drugs / Recombinant Factor VIIa BI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01757405 | Feb 2013 → Nov 2014 | hemophilia A, hemophilia B | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Factor VIIa BI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01757405 ↗ |
| Known as | rFVIIa BI | “Biological: Recombinant Factor VIIa BI (rFVIIa BI)” NCT01757405 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Recombinant Factor VIIa BI (rFVIIa BI)” NCT01757405 ↗ |
| Route | Intravenous | “Administered approximately every 3 hours as an intravenous bolus injection on-demand” NCT01757405 ↗ |